MetaCap

Cerus Corporation (CERS)

NASDAQ: CERSHealth CareMedical/Dental InstrumentsUSD

1.85-0.05 (-2.63%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CERS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$373.62M
EPS (TTM)
-$0.04
52-week range
1.59 – 3.47
Day range
1.82 – 1.95
Volume / Avg
4.51M / 2.12M
Beta
—

52-week range

$1.59$3.47

CERS stock today

On Nov 20, CERS ended the session at $1.85, shedding $0.05 (2.63%), versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 4.51M shares, a sign of unusually heavy trading. Shares are 46.7% below their 52-week high of $3.47, set on Jul 6, 2026 and 16.4% above the 52-week low of $1.59, near the bottom of the past year's range.

CERS is down 10.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 14.2%. Cerus has posted a net loss over the last twelve months (EPS of -$0.04), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cerus

Company profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Industry
Medical/Dental Instruments
CEO
Mr. Vivek K. Jayaraman
Headquarters
Concord, CA
Employees
261
IPO year
1997
Website
cerus.com

Financial highlights

Full financials

In fiscal 2025, Cerus generated $233.8 million in revenue, up 16.1% from fiscal 2024, its 2nd consecutive year of revenue growth. Cerus reported a net loss of $15.6 million, compared with a loss of $20.9 million a year earlier. Operating margin was -3.7%.

Cerus annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$233.80M$201.32M$186.80M$188.31M$159.52M
Growth+16.13%+7.78%-0.81%+18.05%+39.62%
Net income$-15.63M$-20.92M$-37.49M$-42.78M$-54.37M
EPS (diluted)$-0.08$-0.11$-0.21$-0.24$-0.32

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$5.13+177.30%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $6.50

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$0.00 vs $-0.01
Surprise
+100.00%

CERS news

All CERS news

Cerus peers

Health Care sector
CERS peer companies
CompanyPrice% ChgMarket capCompare
MOBIMobia Medical Inc.11.85-0.08%$394.50Mvs CERS
BWAYBrainsWay Ltd. ADR8.48-2.86%$341.35Mvs CERS
EMBCEmbecta Corp.6.02-2.75%$341.09Mvs CERS
SIShoulder Innovations Inc.20.15-0.79%$421.58Mvs CERS
SENSSenseonics Holdings Inc.8.02-9.94%$439.34Mvs CERS
MDXGMiMedx Group Inc3.05-1.93%$445.07Mvs CERS
ANGOAngioDynamics Inc.10.81+0.46%$454.61Mvs CERS
INFUInfuSystems Holdings Inc.14.35+2.06%$287.48Mvs CERS

Indexes, lists and sector

Cerus stock FAQ

What is Cerus's stock price today?

CERS last traded at $1.85 as of Nov 20, 4:00 PM EST, down 2.63% on the day. Prices are delayed at least 15 minutes.

Who is Cerus's CEO?

Mr. Vivek K. Jayaraman is the chief executive officer of Cerus Corporation, which has about 261 employees.

What is the CERS 52-week high?

The 52-week high for CERS is $3.47 and the 52-week low is $1.59. The stock is currently 46.7% below its high.

Compare CERS